FBIO Fortress Biotech: Company Short-Term Debts

Public company logo of Fortress (FBIO)

Fortress Biotech, Inc. (FBIO) manages a network of subsidiaries characterized by volatile revenue and high research expenses, optimizing laboratory supply chains through a unified IT system. The history of short-term debt helps assess leverage risks, where the current metric equals 0.00. Growth potential is based on the monetization of biotech assets, the receipt of royalties, and FDA approvals for new drugs in oncology and dermatology.

FBIO Fortress Biotech Company Short-Term Debt (07/04/2022 - 10/30/2026)

Summary analytical data breakdowns for Fortress Biotech Corp (FBIO)

- stock price and consensus target price:
Stock Price Fortress Biotech|FBIO - Consensus Target
- company stock capitalization data:
Market Capitalization Fortress Biotech, Inc.|FBIO - Total Enterprise Value
- business book valuation details:
Net Assets per Single Share Fortress Biotech|FBIO - Company Book Value|Market Value to Book Value Ratio fortressbiotech.com|FBIO - Aggregate Company Assets
- debt and liquidity details:
Total Debt to Capital Fortress Biotech, Inc.|FBIO - Long-Term Debt to Capital|Short-Term Debt to Equity Fortress Biotech, Inc.|FBIO - Company Aggregate Debt|Debts to Book Capitalization Fortress Biotech, Inc.|FBIO - Long-Term Debt|Company Short-Term Debt Fortress Biotech|Quick Liquidity Indicator fortressbiotech.com
- earnings and multiples data:
FBIO - Net Profit
Fundamental valuation:Fortress Biotech (FBIO)
Manufactured products of Fortress Biotech, Inc.

Monitoring obligations maturing within one year is critical for constructing a defensive portfolio, as these determine the issuer's current liquidity and financial stability. An analysis of Fortress Biotech, Inc. (FBIO) short-term loans and borrowings allows for an assessment of how effectively management balances the debt load with the autonomy of subsidiary startups, ensuring operational flexibility and capital preservation without compromising the development of biomedical projects.

Main competitors

NovoCure - Company Short-Term Debts|Alpha Tau Medical Ltd (DRTS) - Company Current Liabilities|ACRV: Company Short-Term Debts|Short-Term Debt Allarity Therapeutics, Inc. (ALLR)